Sign up USA
Proactive Investors - Run By Investors For Investors

Endo International confirms subsidiary receives grand jury subpoena from US Attorney's Office of Southern District of Florida

In a statement, the company said the subpoena is seeking information relating to products containing the opioid oxymorphone
Drugs
Endo International said it intends to cooperate with the subpoena and any related investigation

Endo International PLC (NASDAQ:ENDP) saw its shares shed 3% in pre-market trading after the company confirmed that its subsidiary, Endo Pharmaceuticals Inc., has received a grand jury subpoena from the US Attorney's Office for the Southern District of Florida.

In a statement, the company said the subpoena is seeking information relating to products containing the opioid oxymorphone.

It said it also is seeking documents including those produced in past or pending lawsuits, as well as those relating to safety and efficacy, overdoses, abuse/misuse and overprescribing, among other issues.

The group said it intends to cooperate with the subpoena and any related investigation.

In pre-market trading in New York, Endo International shares were down 3% at US$7.83.

View full ENDP profile View Profile

Endo Pharmaceuticals Timeline

Newswire
November 24 2014

Related Articles

picture of cannabis plants
March 23 2018
Control of the supply chain offers operational advantages and financial benefits.
lab
March 15 2018
Amryt's lead drug candidate, AP101, is a potential treatment for epidermolysis bullosa, a rare genetic skin disorder for which there is currently no approved treatment
1514990464_biotech_517925923.jpg
January 03 2018
Investors have been cheered by the method used to raise fresh investment, which avoids the need to issue more shares for cash

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use